Clinical trial results:
A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF)

Summary

EudraCT number	2019-000587-23
Trial protocol	FI ES FR DE IT
Global end of trial date	27 February 2025

Results information

Result version number	v2 (current)
This version publication date	31 May 2026
First version publication date	31 January 2026
Version creation reason	

Trial information

Trial identification

Sponsor protocol code	MK-8591A-018

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04223791
WHO universal trial number (UTN)	-
Other trial identifiers	JAPIC-CTI: 205166

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme LLC
Sponsor organisation address	126 East Lincoln Avenue, P.O. Box 2000, Rahway, United States, 07065
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme LLC, ClinicalTrialsDisclosure@msd.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	27 February 2025
Is this the analysis of the primary completion data?	Yes
Primary completion date	26 August 2021
Global end of trial reached?	Yes
Global end of trial date	27 February 2025
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This study will evaluate the safety and efficacy of a switch to Doravirine/Islatravir (DOR/ISL) (MK-8591A) (a fixed dose combination of doravirine 100 mg and islatravir 0.75 mg) in participants living with human immunodeficiency virus-1 (HIV-1) virologically suppressed on a regimen of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that a switch to DOR/ISL (MK-8591A) will be non-inferior to continued treatment with BIC/FTC/TAF as assessed by the proportion of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48. Participants who benefit from their assigned intervention (as determined by investigator) will be able to continue treatment through a 24-week study extension.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	18 February 2020
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	50 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Australia: 37
Country: Number of subjects enrolled	Austria: 48
Country: Number of subjects enrolled	Canada: 18
Country: Number of subjects enrolled	Finland: 10
Country: Number of subjects enrolled	France: 66
Country: Number of subjects enrolled	Germany: 109
Country: Number of subjects enrolled	Italy: 36
Country: Number of subjects enrolled	Japan: 9
Country: Number of subjects enrolled	Puerto Rico: 23
Country: Number of subjects enrolled	Spain: 85
Country: Number of subjects enrolled	United States: 202
Worldwide total number of subjects	643
EEA total number of subjects	354

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	590
From 65 to 84 years	53
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Adult participants living with human immunodeficiency virus-1 (HIV-1) who have been virologically suppressed for ≥3 months and receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) with no history of treatment failure were enrolled.

Period 1

Period 1 title	Base Study (Day 1 to Week 144)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	DOR/ISL

Arm description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Arm type	Experimental
Investigational medicinal product name	Placebo to BIC/FTC/TAF
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily

Investigational medicinal product name	doravirine (DOR)/islatravir (ISL)
Investigational medicinal product code	
Other name	MK-8591A
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg DOR/ 0.75 ISL fixed dose combination (FDC) single tablet taken orally once daily

Arm title	BIC/FTC/TAF

Arm description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Arm type	Active comparator

Investigational medicinal product name	bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily

Investigational medicinal product name	Placebo to FDC DOR/ISL
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Placebo to FDC DOR/ISL in a single tablet taken orally, once daily

Number of subjects in period 1	DOR/ISL	BIC/FTC/TAF
Started	322	321
Treated	322	319
Completed	224	211
Not completed	98	110
Adverse event, serious fatal	2	-
Physician decision	18	7
Consent withdrawn by subject	56	40
Unknown	6	15
Sponsor Decision	11	39
Lost to follow-up	5	8
Protocol deviation	-	1

Period 2

Period 2 title	Extension Study (Week 144 to Week 168)
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes

Arm title	DOR/ISL

Arm description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Arm type	Experimental
Investigational medicinal product name	doravirine (DOR)/islatravir (ISL)
Investigational medicinal product code	
Other name	MK-8591A
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

100 mg DOR/ 0.75 ISL fixed dose combination (FDC) single tablet taken orally once daily

Arm title	BIC/FTC/TAF

Arm description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Arm type	Active comparator
Investigational medicinal product name	bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily

Number of subjects in period 2[1]	DOR/ISL	BIC/FTC/TAF
Started	132	131
Completed	10	2
Not completed	122	129
Physician decision	2	1
Consent withdrawn by subject	28	2
Unknown	-	1
Sponsor Decision	91	124
Lost to follow-up	1	1

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Subset of participants who completed the base study may have been eligible to enter the study extension.

Baseline characteristics

Reporting groups	
Reporting group title	DOR/ISL
Reporting group description:	
Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.	
Reporting group title	BIC/FTC/TAF
Reporting group description:	
Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.	

Reporting group values	DOR/ISL	BIC/FTC/TAF	Total
Number of subjects	322	321	643
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	294	296	590
From 65-84 years	28	25	53
85 years and over	0	0	0
Age Continuous Units: Years			
arithmetic mean	47.6	48.0	
standard deviation	± 12.6	± 11.8	-
Sex: Female, Male Units: Participants			
Female	105	78	183
Male	217	243	460
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	3	2	5
Asian	14	13	27
Native Hawaiian or Other Pacific Islander	2	0	2
Black or African American	59	56	115
White	239	240	479

More than one race	5	7	12
Unknown or Not Reported	0	3	3
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	64	55	119
Not Hispanic or Latino	256	261	517
Unknown or Not Reported	2	5	7

End points

End points reporting groups

Reporting group title	DOR/ISL

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	DOR/ISL

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Primary: Percentage of Participants with Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 copies/mL at Week 48

End point title	Percentage of Participants with Human Immunodeficiency Virus 1 Ribonucleic Acid (HIV-1 RNA) ≥50 copies/mL at Week 48

End point description:

The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the primary outcome measure, the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Primary

End point timeframe:

Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA ≥50 Copies/mL	0.6	0.3		
No Virologic Data in Window	5.6	5.3		
HIV-1 RNA <50 Copies/mL	93.8	94.4		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	non-inferiority[1]
P-value	< 0.001 [2]
Method	Unstratified Miettinen and Nurminen
Parameter estimate	Estimated difference
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.19
upper limit	1.96

Notes:

[1] - Non-inferiority is concluded if the upper bound of the 2-sided multiplicity-adjusted 95% CI for the difference in the percentage of participants with HIV-1 RNA ≥50 copies/mL (DOR/ISL-BIC/FTC/TAF) is less than 4 percentage points.

[2] - p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method.

Primary: Percentage of Participants With One or More Adverse Events (AEs) up to Week 48

End point title	Percentage of Participants With One or More Adverse Events (AEs) up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE up to week 48 is presented. The analysis population consisted of all randomized participants who received ≥1 dose of study intervention. Participants were included in the treatment group corresponding to the study intervention received.

End point type	Primary

End point timeframe:

Up to 48 weeks

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	71.1	74.6		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[3]
Parameter estimate	Difference in % (DOR/ISL- BIC/FTC/TAF)
Point estimate	-3.5
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.4
upper limit	3.4

Notes:

[3] - Difference between treatment groups. Based on Miettinen and Nurminen method.

Primary: Percentage of Participants who Discontinued Study Intervention Due to an AE up to Week 48

End point title	Percentage of Participants who Discontinued Study Intervention Due to an AE up to Week 48

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE up to week 48 is presented. The analysis population consisted of all randomized participants who received ≥1 dose of study intervention. Participants were included in the treatment group corresponding to the study intervention received.

End point type	Primary

End point timeframe:

Up to 48 weeks

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	2.5	2.5		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[4]
Parameter estimate	Difference in % (DOR/ISL- BIC/FTC/TAF)
Point estimate	-0.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.7
upper limit	2.6

Notes:

[4] - Difference between treatment groups; based on Miettinen and Nurminen method

Secondary: Percentage of Participants with HIV-1 RNA ≥50 copies/mL at Week 96

End point title	Percentage of Participants with HIV-1 RNA ≥50 copies/mL at Week 96

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96, is presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA ≥50 Copies/mL	0.6	0.3		
No Virologic Data in Window	14.3	8.8		
HIV-1 RNA <50 Copies/mL	85.1	90.9		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	non-inferiority[5]
P-value	< 0.001 [6]
Method	Unstratified Miettinen and Nurminen
Parameter estimate	Estimated Difference
Point estimate	0.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.19
upper limit	1.96

Notes:

[5] - Non-inferiority is concluded if the upper bound of the 2-sided multiplicity-adjusted 95% CI for the difference in the percentage of participants with HIV-1 RNA ≥50 copies/mL (DOR/ISL minus BIC/FTC/TAF) is less than 4 percentage points. Estimated difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
[6] - p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. The p-value corresponds to a 1-sided Type 1 error of 0.02497.

Secondary: Percentage of Participants with HIV-1 RNA ≥50 copies/mL at Week 144

End point title	Percentage of Participants with HIV-1 RNA ≥50 copies/mL at Week 144

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA ≥50 Copies/mL	0.9	1.3		
No Virologic Data in Window	47.2	33.2		

HIV-1 RNA <50 Copies/mL	51.9	65.5		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[7]
Parameter estimate	Estimated Difference
Point estimate	-0.32
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.36
upper limit	1.6

Notes:

[7] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences, CIs for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 48

End point title	Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 48

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA <50 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA <50 Copies/mL	93.8	94.4		
No Virologic Data in Window	5.6	5.3		
HIV-1 RNA ≥50 Copies/mL	0.6	0.3		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[8]
Parameter estimate	Estimated Difference
Point estimate	-0.57
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.38
upper limit	3.21

Notes:

[8] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences and CIs for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 48

End point title	Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 48

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA <40 copies/mL at Week 48, is presented using the FDA snapshot missing data approach. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	93.2	94.0		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[9]
Parameter estimate	Estimated Difference
Point estimate	-0.88
Confidence interval	
level	95 %
sides	2-sided
lower limit	-4.81
upper limit	3.02

Notes:

[9] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences and CIs for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 96

End point title	Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 96

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA <50 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA <50 copies/mL	85.1	90.9		
No Virologic Data in Window	14.3	8.8		
HIV-1 RNA ≥50 copies/mL	0.6	0.3		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF

Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[10]
Parameter estimate	Estimated Difference
Point estimate	-5.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-10.94
upper limit	-0.79

Notes:

[10] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 96

End point title	Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 96

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA <40 copies/mL at Week 96, is presented using the FDA snapshot missing data approach. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	84.8	90.9		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[11]
Parameter estimate	Estimated Difference
Point estimate	-6.13

Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.28
upper limit	-1.08

Notes:

[11] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 144

End point title	Percentage of Participants with HIV-1 RNA <50 copies/mL at Week 144

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, the percentage of participants with HIV-1 RNA <50 copies/mL at Week 144 is presented using the FDA snapshot missing data approach. The percentage values were rounded to the nearest tenth digit. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)				
HIV-1 RNA <50 copies/mL	51.9	65.5		
No Virologic Data in Window	47.2	33.2		
HIV-1 RNA ≥50 copies/mL	0.9	1.3		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[12]
Parameter estimate	Estimated Difference
Point estimate	-13.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.11
upper limit	-6.04

Notes:

[12] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences and CIs for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 144

End point title	Percentage of Participants with HIV-1 RNA <40 copies/mL at Week 144

End point description:

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. Per protocol, the secondary outcome measure, percentage of participants with HIV-1 RNA <40 copies/mL at Week 144, is presented using the FDA snapshot missing data approach. The analysis population consisted of all participants who received ≥1 dose of study intervention. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	51.9	65.5		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	641
Analysis specification	Pre-specified
Analysis type	other[13]
Parameter estimate	Estimated Difference
Point estimate	-13.65
Confidence interval	
level	95 %
sides	2-sided
lower limit	-21.11
upper limit	-6.04

Notes:

[13] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the unstratified Miettinen and Nurminen method. Estimated Difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Mean Change from Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48

End point title	Mean Change from Baseline in Cluster of Differentiation-positive (CD4+) T-cell Count at Week 48

End point description:

Plasma CD4+ T-cell count was measured in cells/mm^3 for baseline and 48 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 48 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline. The analysis population consisted of all participants who received ≥1 dose of study intervention and had data available, including baseline data available, for CD4+ T-cell count at Week 48. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Baseline and Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	301	298		
Units: cells/mm^3				
arithmetic mean (confidence interval 95%)	-19.66 (-39.78 to 0.45)	40.51 (20.66 to 60.36)		

Statistical analyses

Statistical analysis title	Mean Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	599
Analysis specification	Pre-specified
Analysis type	other[14]
Parameter estimate	Mean difference (DOR/ISL-BIC/FTC/TAF)
Point estimate	-68.09
Confidence interval	
level	95 %
sides	2-sided
lower limit	-94.75
upper limit	-41.43

Notes:

[14] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The Confidence Intervals (CIs) for mean difference in CD4+ T-cell count change from baseline were based on Analysis of Covariance (ANCOVA) model adjusted by baseline CD4+ T-cell count and treatment group.

Secondary: Mean Change from Baseline in CD4+ T-cell count at Week 96

End point title	Mean Change from Baseline in CD4+ T-cell count at Week 96

End point description:

Plasma CD4+ T-cell count was measured in cells/mm^3 for baseline and 96 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 96 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline. The analysis population consisted of all participants who received ≥1 dose of study intervention and had data available, including baseline data available, for CD4+ T-cell count at Week 96. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Baseline and Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	273	290		
Units: cells/mm^3				
arithmetic mean (confidence interval 95%)	5.36 (-19.71 to 30.42)	62.67 (40.44 to 84.90)		

Statistical analyses

Statistical analysis title	Mean Difference in Treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	563
Analysis specification	Pre-specified
Analysis type	other[15]
Parameter estimate	Mean difference (DOR/ISL-BIC/FTC/TAF)
Point estimate	-65.45
Confidence interval	
level	95 %
sides	2-sided
lower limit	-97.02
upper limit	-33.89

Notes:

[15] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The CIs for mean difference in CD4+ T-cell count change from baseline were based on ANCOVA model adjusted by baseline CD4+ T-cell count and treatment group.

Secondary: Mean Change from Baseline in CD4+ T-cell count at Week 144

End point title	Mean Change from Baseline in CD4+ T-cell count at Week 144

End point description:

Plasma CD4+ T-cell count was measured in cells/mm^3 for baseline and 144 weeks by a central laboratory. Baseline measurement of CD4+ T-cell count is defined as the day 1 value for each participant. The mean change from baseline in CD4+ T-cell count at week 144 using the data as observed (DAO) approach is presented. A negative value indicates a mean decrease in CD4+ T-cell count from baseline and a positive value indicates a mean increase in CD4+ T-cell count from baseline. The analysis population consisted of all participants who received ≥1 dose of study intervention and had data available, including baseline data available, for CD4+ T-cell count at Week 144. Participants were included in the treatment group to which they were randomized.

End point type	Secondary

End point timeframe:

Baseline and Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	170	213		
Units: cells/mm^3				
arithmetic mean (confidence interval 95%)	0.48 (-28.69 to 29.64)	66.25 (38.78 to 93.73)		

Statistical analyses

Statistical analysis title	Mean Difference in Treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	383
Analysis specification	Pre-specified
Analysis type	other[16]
Parameter estimate	Mean difference (DOR/ISL-BIC/FTC/TAF)
Point estimate	-78.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-114.63
upper limit	-41.63

Notes:

[16] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The CIs for mean difference in CD4+ T-cell count change from baseline were based on ANCOVA model adjusted by baseline CD4+ T-cell count and treatment group.

Secondary: Number of Participants with Viral Drug Resistance-associated Substitutions at Week 48

End point title	Number of Participants with Viral Drug Resistance-associated Substitutions at Week 48

End point description:

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL having genotypic or phenotypic evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance is presented. The analysis population consisted of participants with data available at Week 48. Per protocol, participants who met the definition of confirmed virologic rebound (two consecutive [2 to 4 weeks apart] occurrences of HIV-1 RNA ≥200 copies/mL) at any time during the study or who discontinued study intervention for another reason and have HIV-1 RNA ≥200 copies/mL at the time of discontinuation. Participants for whom available genotypic or phenotypic data showed evidence of resistance, irrespective of viral load, were also included.

End point type	Secondary

End point timeframe:

Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1[17]	0[18]		
Units: Participants	0			

Notes:

[17] - Participants who met protocol-specified criteria for viral drug resistance analysis in DOR/ISL

[18] - Participants who met protocol-specified criteria for viral drug resistance analysis in BIC/FTC/TAF

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with evidence of viral drug resistance-associated substitutions at Week 96

End point title	Number of Participants with evidence of viral drug resistance-associated substitutions at Week 96

End point description:

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 96 is presented. The analysis population consisted of participants with data available at Week 96. Per protocol, participants who met the definition of confirmed virologic rebound (two consecutive [2 to 4 weeks apart] occurrences of HIV-1 RNA ≥200 copies/mL) at any time during the study or who discontinued study intervention for another reason and have HIV-1 RNA ≥200 copies/mL at the time of discontinuation. Participants for whom available genotypic or phenotypic data showed evidence of resistance, irrespective of viral load, were also included.

End point type	Secondary

End point timeframe:

Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2[19]	0[20]		
Units: Participants	0			

Notes:

[19] - Participants who met protocol-specified criteria for viral drug resistance analysis in DOR/ISL

[20] - Participants who met protocol-specified criteria for viral drug resistance analysis in BIC/FTC/TAF

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with evidence of viral drug resistance-associated substitutions at Week 144

End point title	Number of Participants with evidence of viral drug resistance-associated substitutions at Week 144

End point description:

Viral drug resistance is defined as participants with confirmed HIV-1 RNA ≥400 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrate drug resistance at week 144 is presented. The analysis population consisted of participants with data available at Week 144. Per protocol, participants who met the definition of confirmed virologic rebound (two consecutive [2 to 4 weeks apart] occurrences of HIV-1 RNA ≥200 copies/mL) at any time during the study or who discontinued study intervention for another

reason and have HIV-1 RNA ≥200 copies/mL at the time of discontinuation. Participants for whom available genotypic or phenotypic data showed evidence of resistance, irrespective of viral load, were also included.

End point type	Secondary

End point timeframe:

Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2[21]	0[22]		
Units: Participants	0			

Notes:

[21] - Participants who met protocol-specified criteria for viral drug resistance analysis in DOR/ISL

[22] - Participants who met protocol-specified criteria for viral drug resistance analysis in BIC/FTC/TAF

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Body Weight at Week 48

End point title	Change from Baseline in Body Weight at Week 48

End point description:

Body weight was measured and recorded at baseline and week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 48 is presented. The analysis population consisted of participants who received ≥1 dose of study intervention and were included in the treatment group corresponding to the study intervention received. The analysis population included participants with baseline and at least one postbaseline test result and had data available for this outcome measure at Week 48.

End point type	Secondary

End point timeframe:

Baseline and Week 48

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	306	302		
Units: kilogram (kg)				
arithmetic mean (standard deviation)	0.23 (± 4.19)	0.55 (± 4.40)		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF

Number of subjects included in analysis	608
Analysis specification	Pre-specified
Analysis type	superiority[23]
P-value	= 0.392 [24]
Method	ANCOVA
Parameter estimate	Treatment Difference
Point estimate	-0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.99
upper limit	0.39

Notes:

[23] - ANCOVA Model included terms for baseline weight, sex, race, and treatment. Treatment difference is treatment difference for DOR/ISL group-BIC/FTC/TAF group.
[24] - Model included terms for baseline weight, sex, race, and treatment.

Secondary: Change from Baseline in Body Weight at Week 96

End point title	Change from Baseline in Body Weight at Week 96

End point description:

Body weight was measured and recorded at baseline and week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 96 is presented. The analysis population consisted of participants who received ≥1 dose of study intervention and were included in the treatment group corresponding to the study intervention received. The analysis population included participants with baseline and at least one postbaseline test result and had data available for this outcome measure at Week 96.

End point type	Secondary

End point timeframe:

Baseline and Week 96

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	277	293		
Units: kilogram (kg)				
arithmetic mean (standard deviation)	0.29 (± 5.33)	0.72 (± 5.72)		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	570
Analysis specification	Pre-specified
Analysis type	superiority[25]
P-value	= 0.3263 [26]
Method	ANCOVA
Parameter estimate	Treatment Difference
Point estimate	-0.45

Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.34
upper limit	0.45

Notes:

[25] - ANCOVA model included terms for baseline weight, sex, race, and treatment. Treatment difference is treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
[26] - Model included terms for baseline weight, sex, race, and treatment.

Secondary: Change from Baseline in Body Weight at Week 144

End point title	Change from Baseline in Body Weight at Week 144

End point description:

Body weight was measured and recorded at baseline and week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. The mean change from baseline in body weight at week 144 is presented. The analysis population consisted of participants who received ≥1 dose of study intervention and were included in the treatment group corresponding to the study intervention received. The analysis population included participants with baseline and at least one postbaseline test result and had data available for this outcome measure at Week 144.

End point type	Secondary

End point timeframe:

Baseline and Week 144

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	216	236		
Units: kilogram (kg)				
arithmetic mean (standard deviation)	0.63 (± 6.67)	0.84 (± 6.41)		

Statistical analyses

Statistical analysis title	Difference between treatment groups
Comparison groups	DOR/ISL v BIC/FTC/TAF
Number of subjects included in analysis	452
Analysis specification	Pre-specified
Analysis type	other[27]
Parameter estimate	Treatment Difference
Point estimate	-0.13
Confidence interval	
level	95 %
sides	2-sided
lower limit	-1.33
upper limit	1.06

Notes:

[27] - Type of statistical test 'other' denotes no hypothesis testing was conducted. The 95% CIs for treatment difference were calculated from ANCOVA model with terms for baseline weight, sex, race, and treatment. Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.

Secondary: Percentage of Participants With One or More AEs

End point title	Percentage of Participants With One or More AEs

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The analysis population consisted of all randomized participants who received ≥1 dose of study intervention. Participants were included in the treatment group corresponding to the study intervention received.

End point type	Secondary

End point timeframe:

Up to approximately 55 months

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	96.3	94.4		

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Participants who Discontinued Study Intervention Due to an AE

End point title	Percentage of Participants who Discontinued Study Intervention Due to an AE

End point description:

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The analysis population consisted of all randomized participants who received ≥1 dose of study intervention. Participants were included in the treatment group corresponding to the study intervention received.

End point type	Secondary

End point timeframe:

Up to approximately 40 months

End point values	DOR/ISL	BIC/FTC/TAF		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	322	319		
Units: Percentage of Participants				
number (not applicable)	22.0	6.9		

Statistical analyses

No statistical analyses for this end point

Adverse events information

Timeframe for reporting adverse events:

Up to approximately 55 months

Adverse event reporting additional description:

All cause mortality: all randomized participants; AEs: all randomized participants who got ≥1 dose of study drug. Reported by base & extension. Per protocol, participants with specific drops in CD4+/total lymphocyte count reported as 'post treatment follow up'; all pregnancy-related AEs were collected & reported by arm that participants enrolled.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	27.1

Reporting groups

Reporting group title	DOR/ISL: Base Study Week 0 - Week 48

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	DOR/ISL: Base Study Week 48-Week 96

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	DOR/ISL: Base Study Week 96-Week 144

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	DOR/ISL: Open-Label Extension Week 144-Week 168

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	DOR/ISL: Post-Treatment Follow-Up

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received a once daily (QD) fixed dose combination (FDC) of 100 mg doravirine (DOR)/0.75 mg islatravir (ISL) for 144 weeks; and a placebo to BIC/FTC/TAF for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24

weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF: Base Study Week 48 - Week 96

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF: Base Study Week 0 - Week 48

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF: Base Study Week 96 - Week 144

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Reporting group title	BIC/FTC/TAF: Post-Treatment Follow-Up

Reporting group description:

Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months with no history of treatment failure who were previously treated with bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) received once daily (QD) 50 mg bictegravir (BIC), 200 mg emtricitabine (FTC), 25 mg tenofovir alafenamide (TAF) for 144 weeks, and placebo to fixed dose combination (FDC) DOR/ISL for 96 weeks. At Week 144, participants who consent to enter the optional open-label study extension will continue to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

Serious adverse events	DOR/ISL: Base Study Week 0 - Week 48	DOR/ISL: Base Study Week 48- Week 96	DOR/ISL: Base Study Week 96- Week 144
Total subjects affected by serious adverse events			
subjects affected / exposed	14 / 322 (4.35%)	19 / 305 (6.23%)	7 / 266 (2.63%)
number of deaths (all causes)	0	2	0
number of deaths resulting from adverse events	0	2	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Breast cancer metastatic			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Non-cardiac chest pain			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Imprisonment			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance use			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst torsion			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			

subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Psychiatric disorders			
Bipolar disorder			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug abuse			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Multiple injuries			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	2 / 322 (0.62%)	1 / 305 (0.33%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 2	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriospasm coronary			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			

subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brachial plexopathy			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			

subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic stroke			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			

subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic artery aneurysm			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			

Goitre			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myositis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis B			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	1 / 322 (0.31%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	1 / 322 (0.31%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Clostridium difficile colitis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giardiasis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	1 / 322 (0.31%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			

subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	1 / 266 (0.38%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis			

subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetic ketoacidosis			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	0 / 322 (0.00%)	1 / 305 (0.33%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 322 (0.00%)	0 / 305 (0.00%)	0 / 266 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	DOR/ISL: Open-Label Extension Week 144-Week 168	DOR/ISL: Post-Treatment Follow-Up	BIC/FTC/TAF: Base Study Week 48 - Week 96
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 132 (0.00%)	3 / 196 (1.53%)	11 / 301 (3.65%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			

subjects affected / exposed	0 / 132 (0.00%)	1 / 196 (0.51%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Social circumstances			
Imprisonment			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance use			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst torsion			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Bipolar disorder			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug abuse			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriospasm coronary			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 132 (0.00%)	1 / 196 (0.51%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brachial plexopathy			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic stroke			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic artery aneurysm			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myositis			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	0 / 132 (0.00%)	1 / 196 (0.51%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis B			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giardiasis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	1 / 301 (0.33%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetic ketoacidosis			

subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 132 (0.00%)	0 / 196 (0.00%)	0 / 301 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	BIC/FTC/TAF: Base Study Week 0 - Week 48	BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168	BIC/FTC/TAF: Base Study Week 96 - Week 144
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 319 (5.02%)	1 / 131 (0.76%)	6 / 281 (2.14%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lipoma			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant melanoma			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Prostate cancer			

subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Squamous cell carcinoma			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypertensive urgency			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Social circumstances			
Imprisonment			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Substance use			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ovarian cyst torsion			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Bipolar disorder			

subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Delirium			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Depression			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Drug abuse			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Suicidal ideation			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Ligament sprain			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Multiple injuries			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skull fracture			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tibia fracture			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular pseudoaneurysm			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aortic valve incompetence			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Arteriospasm coronary			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atrial fibrillation			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure congestive			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac tamponade			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mitral valve incompetence			

subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial ischaemia			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocarditis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Supraventricular tachycardia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Brachial plexopathy			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebral haemorrhage			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cerebrovascular accident			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoaesthesia			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic stroke			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Status epilepticus			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thalamic stroke			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Inguinal hernia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Splenic artery aneurysm			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Umbilical hernia			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 319 (0.00%)	1 / 131 (0.76%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholelithiasis			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ureteric obstruction			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Myositis			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteoarthritis			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute hepatitis B			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Atypical pneumonia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis			

subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis escherichia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocarditis bacterial			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Giardiasis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurosyphilis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteomyelitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia influenzal			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia pneumococcal			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Soft tissue infection			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vestibular neuronitis			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Diabetic ketoacidosis			

subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypovolaemia			
subjects affected / exposed	0 / 319 (0.00%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Type 2 diabetes mellitus			
subjects affected / exposed	1 / 319 (0.31%)	0 / 131 (0.00%)	0 / 281 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	BIC/FTC/TAF: Post-Treatment Follow-Up		
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 152 (0.00%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast cancer metastatic			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Lipoma			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Malignant melanoma			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Prostate cancer			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Squamous cell carcinoma			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypertensive urgency			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Non-cardiac chest pain			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Social circumstances			
Imprisonment			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Substance use			

subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Reproductive system and breast disorders			
Cervical dysplasia			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ovarian cyst torsion			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory, thoracic and mediastinal disorders			
Asthma			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Bipolar disorder			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Delirium			

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Depression				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Drug abuse				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Suicidal ideation				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Injury, poisoning and procedural complications				
Ligament sprain				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Multiple injuries				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Skull fracture				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Tibia fracture				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vascular pseudoaneurysm				

subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Acute myocardial infarction			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Aortic valve incompetence			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Arteriospasm coronary			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Atrial fibrillation			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure congestive			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac tamponade			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mitral valve incompetence			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocardial ischaemia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Myocarditis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Supraventricular tachycardia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Nervous system disorders				
Brachial plexopathy				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebral haemorrhage				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cerebrovascular accident				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoaesthesia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Ischaemic stroke				

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Status epilepticus				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Syncope				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Thalamic stroke				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastrointestinal disorders				
Colitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Inguinal hernia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Splenic artery aneurysm				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Umbilical hernia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				

subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Cholecystitis acute			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cholelithiasis			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ureteric obstruction			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Endocrine disorders			
Goitre			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Myositis			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteoarthritis			

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Infections and infestations				
Acute hepatitis B				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Atypical pneumonia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
COVID-19 pneumonia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cellulitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Clostridium difficile colitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis escherichia				

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Endocarditis bacterial				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Giardiasis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes zoster				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neurosyphilis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Osteomyelitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia influenzal				

subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia pneumococcal				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyelonephritis acute				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Soft tissue infection				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vestibular neuronitis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Metabolism and nutrition disorders				
Diabetic ketoacidosis				
subjects affected / exposed	0 / 152 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypovolaemia				

subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	DOR/ISL: Base Study Week 0 - Week 48	DOR/ISL: Base Study Week 48- Week 96	DOR/ISL: Base Study Week 96- Week 144
Total subjects affected by non-serious adverse events			
subjects affected / exposed	85 / 322 (26.40%)	104 / 305 (34.10%)	151 / 266 (56.77%)
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	1 / 322 (0.31%)	28 / 305 (9.18%)	63 / 266 (23.68%)
occurrences (all)	1	28	75
Lymphocyte count decreased			
subjects affected / exposed	1 / 322 (0.31%)	32 / 305 (10.49%)	86 / 266 (32.33%)
occurrences (all)	1	32	108
Vascular disorders			
Hypertension			
subjects affected / exposed	6 / 322 (1.86%)	3 / 305 (0.98%)	5 / 266 (1.88%)
occurrences (all)	6	3	5
Nervous system disorders			
Headache			
subjects affected / exposed	26 / 322 (8.07%)	14 / 305 (4.59%)	3 / 266 (1.13%)
occurrences (all)	43	38	7
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	8 / 322 (2.48%)	7 / 305 (2.30%)	7 / 266 (2.63%)
occurrences (all)	8	7	7
Musculoskeletal and connective tissue disorders			
Arthralgia			

subjects affected / exposed	16 / 322 (4.97%)	8 / 305 (2.62%)	9 / 266 (3.38%)
occurrences (all)	20	9	10
Back pain			
subjects affected / exposed	13 / 322 (4.04%)	9 / 305 (2.95%)	9 / 266 (3.38%)
occurrences (all)	14	11	9
Infections and infestations			
COVID-19			
subjects affected / exposed	19 / 322 (5.90%)	40 / 305 (13.11%)	33 / 266 (12.41%)
occurrences (all)	19	42	35
Nasopharyngitis			
subjects affected / exposed	9 / 322 (2.80%)	11 / 305 (3.61%)	16 / 266 (6.02%)
occurrences (all)	11	12	17

Non-serious adverse events	DOR/ISL: Open-Label Extension Week 144-Week 168	DOR/ISL: Post-Treatment Follow-Up	BIC/FTC/TAF: Base Study Week 48 - Week 96
Total subjects affected by non-serious adverse events			
subjects affected / exposed	34 / 132 (25.76%)	14 / 196 (7.14%)	86 / 301 (28.57%)
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	15 / 132 (11.36%)	0 / 196 (0.00%)	4 / 301 (1.33%)
occurrences (all)	16	0	4
Lymphocyte count decreased			
subjects affected / exposed	21 / 132 (15.91%)	0 / 196 (0.00%)	8 / 301 (2.66%)
occurrences (all)	21	0	8
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 132 (0.76%)	0 / 196 (0.00%)	6 / 301 (1.99%)
occurrences (all)	1	0	6
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 132 (0.76%)	1 / 196 (0.51%)	6 / 301 (1.99%)
occurrences (all)	1	9	6
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	2 / 132 (1.52%)	2 / 196 (1.02%)	7 / 301 (2.33%)
occurrences (all)	2	3	7
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	1 / 132 (0.76%)	1 / 196 (0.51%)	14 / 301 (4.65%)
occurrences (all)	1	1	15
Back pain			
subjects affected / exposed	0 / 132 (0.00%)	1 / 196 (0.51%)	6 / 301 (1.99%)
occurrences (all)	0	1	6
Infections and infestations			
COVID-19			
subjects affected / exposed	2 / 132 (1.52%)	5 / 196 (2.55%)	45 / 301 (14.95%)
occurrences (all)	2	5	47
Nasopharyngitis			
subjects affected / exposed	1 / 132 (0.76%)	4 / 196 (2.04%)	11 / 301 (3.65%)
occurrences (all)	1	7	11

Non-serious adverse events	BIC/FTC/TAF: Base Study Week 0 - Week 48	BIC/FTC/TAF: Open-Label Extension Week 144 - Week 168	BIC/FTC/TAF: Base Study Week 96 - Week 144
Total subjects affected by non-serious adverse events			
subjects affected / exposed	93 / 319 (29.15%)	13 / 131 (9.92%)	101 / 281 (35.94%)
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	0 / 319 (0.00%)	6 / 131 (4.58%)	28 / 281 (9.96%)
occurrences (all)	0	6	35
Lymphocyte count decreased			
subjects affected / exposed	0 / 319 (0.00%)	6 / 131 (4.58%)	28 / 281 (9.96%)
occurrences (all)	0	6	31
Vascular disorders			
Hypertension			
subjects affected / exposed	16 / 319 (5.02%)	1 / 131 (0.76%)	3 / 281 (1.07%)
occurrences (all)	16	1	3
Nervous system disorders			
Headache			
subjects affected / exposed	22 / 319 (6.90%)	0 / 131 (0.00%)	1 / 281 (0.36%)
occurrences (all)	22	0	2
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	20 / 319 (6.27%)	0 / 131 (0.00%)	2 / 281 (0.71%)
occurrences (all)	21	0	2
Musculoskeletal and connective tissue			

disorders			
Arthralgia			
subjects affected / exposed	19 / 319 (5.96%)	0 / 131 (0.00%)	8 / 281 (2.85%)
occurrences (all)	20	0	9
Back pain			
subjects affected / exposed	17 / 319 (5.33%)	1 / 131 (0.76%)	8 / 281 (2.85%)
occurrences (all)	17	1	8
Infections and infestations			
COVID-19			
subjects affected / exposed	18 / 319 (5.64%)	0 / 131 (0.00%)	46 / 281 (16.37%)
occurrences (all)	19	0	47
Nasopharyngitis			
subjects affected / exposed	3 / 319 (0.94%)	3 / 131 (2.29%)	10 / 281 (3.56%)
occurrences (all)	3	3	10

Non-serious adverse events	BIC/FTC/TAF: Post-Treatment Follow-Up		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 152 (0.00%)		
Investigations			
CD4 lymphocytes decreased			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences (all)	0		
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences (all)	0		
Gastrointestinal disorders			
Diarrhoea			
subjects affected / exposed	0 / 152 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			

Arthralgia subjects affected / exposed occurrences (all) Back pain subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0 0 / 152 (0.00%) 0		
Infections and infestations COVID-19 subjects affected / exposed occurrences (all) Nasopharyngitis subjects affected / exposed occurrences (all)	0 / 152 (0.00%) 0 0 / 152 (0.00%) 0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
09 June 2020	Amendment 02: The protocol was amended to: (1) update the hypothesis testing strategy in the statistical analysis plan, (2) update the prohibited concomitant therapies, and (3) allow participants to rescreen one time following approval from the Sponsor.
14 May 2021	Amendment 03: The protocol was amended to: (1) extend study intervention, open-label, from 96 weeks to 144 weeks for all participants, (2) add option for Group 2 to receive open-label DOR/ISL from Week 144 to Week 156 (a 12-week safety monitoring period before being offered enrollment in DOR/ISL rollover study), (3) offer the option to continue study intervention for participants who become pregnant, (4) add a discontinuation criterion if a participant chooses to breastfeed.
15 February 2022	Amendment 06: Given the findings of decreases in CD4+ T-cell and total lymphocyte counts in clinical studies evaluating ISL, the protocol is being amended to increase the frequency of monitoring of CD4+ T-cell and total lymphocyte counts and to specify the management of participants who meet protocol-defined decreases in CD4+ T-cell and/or total lymphocyte counts.
30 November 2022	Amendment 08: This protocol was amended to allow Group 1/Group 2 participants who continue to benefit (as determined by the investigator) from their assigned study intervention to continue their assigned study intervention through a study extension after Week 144. This extension will continue for up to 24 additional weeks (up to maximum Week 168) or until participants have the option to enroll in a DOR/ISL 100-mg/0.25-mg study; whichever is sooner. Participants choosing not to enroll in a DOR/ISL 100 mg/0.25 mg study, will transition to commercially available ART as soon as possible.
30 May 2024	Amendment 09: The protocol was amended to revise the post-treatment management of participants with specific decreases in CD4+ T-cell or total lymphocyte counts. The recovery criteria were revised to account for normal physiologic variability in CD4+ T-cell or total lymphocyte counts and the frequency of monitoring was updated to minimize the burden on study participants

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported